Puerto Rico's Medical Device Cluster Is Quietly One of the Densest in the World

There is a specific thing that happens when you drive from Caguas toward Juncos, or along the north coast through Manatí and Barceloneta. You pass facility after facility, and a surprising number of them make things that end up inside human bodies.

Puerto Rico's medical device concentration is one of those facts that industry people take for granted and everyone else finds surprising. Orthopedic implants, cardiovascular devices, surgical instruments, diagnostics hardware, single-use systems. The island has been doing this for decades, at volume, under FDA oversight.

What makes it worth writing about is not the history. It is what that density does for the next company that shows up.

Why clustering matters more for devices than for most industries

Device manufacturing has a dependency problem. You need sterilization. You need validated cleanrooms. You need precision machining and tooling. You need test labs that understand your standards. You need calibration services. You need people who have done design transfer before and will not panic when the first verification build fails.

In a place with no device history, you build all of that yourself or fly it in. Both are slow and expensive.

On an island where a dozen large device operations have been running for thirty years, most of it already exists. The sterilization capacity is there because someone else needed it first. The machine shops exist because they have been making components for your competitors. The calibration and test providers exist because the market supported them.

This is the part that does not show up in a tax comparison and tends to decide projects anyway.

The talent compounding effect

Device work demands a specific professional profile: engineers who are comfortable inside a quality system and treat documentation as part of the engineering rather than an afterthought.

That profile is unusually common in Puerto Rico, for the simple reason that a lot of people have spent their careers building it. An engineer with fifteen years on the island has likely worked through multiple design transfers, several audits, a few recalls somewhere in the supply chain, and at least one process that nobody could get to behave.

You cannot hire that quickly in a greenfield location. You can hire it here, and the people you hire will not need a six-month orientation to the concept of design control.

Where the research credit actually lands

This is where device companies consistently undercount themselves.

Puerto Rico's current framework is Act 60-2019, which replaced the earlier statutes including Act 73-2008 (Legacy). The research and development activity credit sits at §3030.01, modeled at two fixed rates: 50 percent on direct R&D investment deployed in Puerto Rico into experimental activities, and 20 percent on indirect R&D investment deployed outside Puerto Rico or into incidental activities.

A modern device operation generates a large amount of genuinely experimental work and files most of it under engineering.

Design verification testing where the product fails and the team has to understand why is development. Design transfer, where a process that worked in a lab has to work on a line, is almost always development, because the problems that surface at transfer are the definition of technical uncertainty. Process validation that required real investigation rather than box-ticking is development. Sterilization method development, particularly when a material reacts badly to the standard approach, is development. Packaging and shelf-life work with real unknowns is development.

What is not development is producing devices to a validated process, running routine incoming inspection, or performing a qualification that was never in doubt.

The line, as always, is whether anyone was genuinely uncertain at the start.

The documentation advantage nobody uses

Here is the odd thing about device companies and credit claims. You have better documentation than almost any other industry, and you usually cannot use it.

Your design history file is a near-perfect record of technical investigation. Protocols, reports, failures, design changes and the reasoning behind them, all controlled and dated. A reviewer could not ask for better evidence that systematic experimentation occurred.

What is typically missing is the financial bridge. Nobody tracked which engineers spent which hours on which development project, because the quality system does not care about cost allocation and the finance system does not care about technical content.

Building that bridge is not difficult. It requires defining development projects at the start, tagging engineering time to them, and writing a short technical summary at close. The DHF then becomes supporting evidence rather than an unusable archive.

The reshoring angle for devices specifically

Medical device supply chains got a hard lesson in concentration risk, and the policy response has favored domestic production. Puerto Rico is domestic, has existing device capability, and costs less to operate than a mainland site.

For device companies specifically, there is an additional wrinkle that helps. Moving a device manufacturing site is a regulatory event. You do not do it casually, and once you have done it you are unlikely to do it again soon. That makes the location decision unusually consequential and unusually sticky.

Companies that have thought this through tend to conclude that if they are going to absorb the cost of a move, they should move somewhere they will not have to leave.

What to be realistic about

Power continuity is not optional for a device operation. A lost sterilization cycle or an interrupted cleanroom is expensive and potentially a quality event. Plan and fund redundancy from the start.

Specialized talent in narrow disciplines is competitive. Expect to pay market and to develop some capability internally.

And the incentive position comes from a decree, which is a negotiated document with conditions attached. Nothing in this article is a statement about what your decree would contain.

Everything here is indicative advisory context and should be confirmed against your own facts and current administrative practice.

The useful summary

If you make devices and you are evaluating Puerto Rico, the infrastructure question is largely answered and the talent question is largely answered. Those are the two that usually kill a location decision.

What is left is your own analysis of which development work you do, where it happens, and whether you can prove it. That is a smaller question than it sounds, and it is one you can answer in a few weeks rather than a few quarters.